Dawood Sayed, MD
Pain Medicine · Kansas City, KSNPI 1194942219
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Nevro Corp. at 28.7% of the total. Reporting peaked in 2019 at $172,714 and has fallen 80.4% since, to $33,790 in 2025. Among pain medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 759 payments — averaging $855.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$187K
- Saluda Medical Americas, Inc.$150K
- Painteq LLC$81K
- Abbott$56K
- Vertos Medical, Inc.$42K
- Vertiflex, Inc.$32K
- plus $103K from 18 others
Across 418 payments — averaging $2630.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$278K
- Saluda Medical Americas, Inc.$165K
- Boston Scientific$141K
- Mesoblast, Inc.$115K
- Nalu Medical, Inc.$112K
- MML US, Inc.$86K
- plus $201K from 6 others
Across 7 payments — averaging $1152.86 each. An ownership or investment interest held by the physician or an immediate family member.
- SPR Therapeutics, Inc$8K
What the payments were for
- Consulting fees$344,63053%
- Speaking & faculty fees$207,50332%
- Travel & lodging$27,4714%
- Food & beverage$34,5695%
- Education$23,1004%
- Entertainment$640%
- Ownership interest$12,1332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 305 | $186,659 |
| Saluda Medical Americas, Inc. | 81 | $149,512 |
| Painteq LLC | 116 | $81,041 |
| Abbott | 90 | $55,509 |
| Vertos Medical, Inc. | 18 | $42,059 |
| Vertiflex, Inc. | 27 | $31,599 |
| Medtronic(2 entities) | 34 | $30,596 |
| MML US, Inc. | 23 | $23,577 |
| Surgentec | 5 | $20,684 |
| Flowonix Medical Incorporated | 2 | $19,684 |
| Merit Medical Systems Inc | 1 | $2,725 |
| Boston Scientific | 9 | $1,935 |
| Spinal Simplicity, LLC | 19 | $1,073 |
| Biotronik NRO, Inc. | 5 | $545 |
| SPR Therapeutics, Inc | 3 | $544 |
| Stryker | 6 | $541 |
| Relievant Medsystems, Inc. | 3 | $437 |
| Globus Medical | 5 | $263 |
| Curonix LLC | 1 | $129 |
| Stratus Medical, LLC | 1 | $122 |
| Averitas Pharma Inc. | 1 | $122 |
| Foundation Fusion Solutions, LLC | 1 | $64 |
| Nalu Medical, Inc. | 2 | $32 |
| AbbVie | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza Spinal Cord Stimulation System$134,238
- Evoke SCS$130,201
- PAINTEQ$79,091
- Omnia$47,240
- mild Device Kit$41,853
- PROCLAIM$41,607
- Superion ISS$30,976
- ReActiv8$23,113
- Prometra II$19,684
- INTELLIS$19,574
- 3D GraftRasp System$18,297
- Evoke$18,086
- Proclaim DRG IPG$8,225
- RESTORE$5,500
- Inflate FX$2,200
- IonicRF Generator$2,000
- TiLink, Ion$1,975
- Neuromodulation Dspsbls and Accs$1,750
- GENERAL PAIN MANAGEMENT$1,650
- HA MINUTEMAN G3-R$655
How this compares
$649,470 in reported general payments places this provider in the 95th percentile of 64 pain medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 95 | $1,984 |
| Gabapentin | 103 | $1,919 |
| Tizanidine Hcl | 114 | $1,148 |
| Pregabalin | 14 | $833 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $539 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 32 | $267 |
| Meloxicam | 32 | $80 |
| Lorazepam | 18 | $78 |
| Cephalexin | 14 | $61 |
| Topiramate | 12 | $41 |
| Tramadol Hcl | 17 | $40 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Kansas City
- Usman LatifKansas City$734K
- Andrea ChadwickKansas City$269K
- Christopher LamKansas City$31K
- Samuel PattonKansas City$30K
- Edward BraunKansas City$12K
- James KindscherKansas City$8K
- Sarafina KankamKansas City$3K
- Brian JonesKansas City$792
- Grace ShihKansas City$443
- Thomas SmithKansas City$164
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.